Cogent Biosciences Inc (COGT)

Apr 05, 2026

A Look At Cogent Biosciences (COGT) Valuation After FDA Acceptance Of Bezuclastinib NDA - Sahm

Apr 05, 2026

Apr 04, 2026

COGT Earning Date, Earning Analysis and Earning Prediction - intellectia.ai

Apr 04, 2026

Apr 04, 2026

Cogent Biosciences Inc To Discuss Full SUMMIT Data at ASH Transcript - GuruFocus

Apr 04, 2026

Apr 03, 2026

[Form 4] Cogent Biosciences, Inc. Insider Trading Activity - Stock Titan

Apr 03, 2026

Apr 03, 2026

Analysts’ Top Healthcare Picks: Abbott Laboratories (ABT), Cogent Biosciences (COGT) - The Globe and Mail

Apr 03, 2026

Apr 03, 2026

Technical Reactions to COGT Trends in Macro Strategies - Stock Traders Daily

Apr 03, 2026

Apr 02, 2026

Cogent Biosciences, Inc.Common Stock (NQ: COGT - The Chronicle-Journal

Apr 02, 2026

Apr 02, 2026

Cogent Biosciences, Inc. (COGT) stock price, news, quote and history - Yahoo Finance UK

Apr 02, 2026

Apr 02, 2026

Guggenheim Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45 - Moomoo

Apr 02, 2026

Apr 02, 2026

Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy' (NASDAQ:COGT) - Seeking Alpha

Apr 02, 2026

Apr 02, 2026

Dip Buying: What are analysts price targets for Cogent Biosciences Inc2026 Top Decliners & Risk Controlled Daily Trade Plans - baoquankhu1.vn

Apr 02, 2026

Apr 02, 2026

COGT Forecast, Price Target & Analyst Ratings | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill

Apr 02, 2026

Apr 02, 2026

Cogent Biosciences (COGT) Is Up 5.5% After FDA NDA Filing For Bezuclastinib In GISTHas The Bull Case Changed? - Sahm

Apr 02, 2026

Apr 01, 2026

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors - Investing News Network

Apr 01, 2026

Apr 01, 2026

Cogent Biosciences (NASDAQ:COGT) Stock Price Down 10.2%Should You Sell? - MarketBeat

Apr 01, 2026

Apr 01, 2026

Biotech Stocks To ConsiderApril 1st - MarketBeat

Apr 01, 2026

Apr 01, 2026

Cogent Biosciences (COGT) Advances Bezuclastinib Application - GuruFocus

Apr 01, 2026

Apr 01, 2026

Cogent Biosciences Submits New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors in US - MarketScreener

Apr 01, 2026

Apr 01, 2026

Cogent Biosciences Submits New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors - MarketScreener

Apr 01, 2026

Apr 01, 2026

Cogent files new GIST drug after trial cut progression risk 50% - Stock Titan

Apr 01, 2026

Mar 31, 2026

Fairmount funds sells Cogent Biosciences (COGT) shares for $242.6m By Investing.com - Investing.com Canada

Mar 31, 2026

Mar 31, 2026

COGT (NASDAQ) Form 144 shows proposed 7.0M share sale after conversion - Stock Titan

Mar 31, 2026

Mar 30, 2026

Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts - Proactive financial news

Mar 30, 2026

Mar 30, 2026

Hennion & Walsh Asset Management Inc. Buys 37,938 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat

Mar 30, 2026

Mar 29, 2026

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding - AOL.com

Mar 29, 2026

Mar 29, 2026

Stifel Initiates Coverage of Cogent Biosciences (COGT) with Hold Recommendation - MSN

Mar 29, 2026

Mar 28, 2026

COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - MSN

Mar 28, 2026

Mar 28, 2026

Assenagon Asset Management S.A. Trims Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat

Mar 28, 2026

Mar 27, 2026

Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers - TipRanks

Mar 27, 2026

Mar 27, 2026

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - AOL.com

Mar 27, 2026

Mar 26, 2026

Vanguard disaggregates holdings; Cogent Biosciences (COGT) shows 0% ownership - Stock Titan

Mar 26, 2026

Mar 25, 2026

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch - AOL.com

Mar 25, 2026

Mar 25, 2026

Aug Analyst Calls: Is Cogent Biosciences Inc forming a double bottomPortfolio Return Report & Daily Profit Maximizing Tips - baoquankhu1.vn

Mar 25, 2026

Mar 25, 2026

Assessing Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Rising Institutional Interest - Sahm

Mar 25, 2026

Mar 23, 2026

A Look At Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Shifting Institutional Positions - Yahoo Finance

Mar 23, 2026

Mar 23, 2026

Trading the Move, Not the Narrative: (COGT) Edition - Stock Traders Daily

Mar 23, 2026

Mar 21, 2026

RTW Investments Increases Cogent Biosciences Stake to 2.7% of PortfolioNews and Statistics - IndexBox

Mar 21, 2026

Mar 21, 2026

Kynam Capital Reduces Stake in Cogent Biosciences by $48 Million - Intellectia AI

Mar 21, 2026

Mar 21, 2026

Kynam Capital Sells $48M in Cogent Biosciences Shares | Q4 2025 Portfolio UpdateNews and Statistics - IndexBox

Mar 21, 2026

Mar 21, 2026

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch - The Motley Fool

Mar 21, 2026

Mar 21, 2026

LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo

Mar 21, 2026

Mar 20, 2026

Biotech share surges 372% before being sold as latest selection climbs 40% in 2026 - Bitget

Mar 20, 2026

Mar 20, 2026

FDA accepts Cogent’s drug filing for treatment of rare blood disorder - MSN

Mar 20, 2026

Mar 19, 2026

Cogent Biosciences stock climbs after FDA accepts key drug application - MSN

Mar 19, 2026

Mar 19, 2026

HC Wainwright Analysts Lift Earnings Estimates for COGT - MarketBeat

Mar 19, 2026

Mar 19, 2026

Is Cogent Biosciences (COGT) one of the best multibagger stocks to buy according to billionaires? - MSN

Mar 19, 2026